Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
08:00am, Sunday, 28'th Jan 2024
Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
04:17pm, Friday, 26'th Jan 2024
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.
AbbVie And Merck: Defensive Healthcare Plays Providing Income
12:24pm, Friday, 26'th Jan 2024
Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive heal
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Thursday, 25'th Jan 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
09:56am, Wednesday, 24'th Jan 2024
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
08:45am, Tuesday, 23'rd Jan 2024
Merck plans to buy biotech Harpoon Therapeutics. Harpoon's platform is powerful, and it could produce many opportunities.
Merck (MRK) Laps the Stock Market: Here's Why
06:56pm, Monday, 22'nd Jan 2024
Merck (MRK) concluded the recent trading session at $119.43, signifying a +0.45% move from its prior day's close.
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
06:45am, Friday, 19'th Jan 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1.
The 3 Best Dividend Growth Stocks to Buy in January 2024
10:47am, Wednesday, 17'th Jan 2024
Within the dividend stock portfolio, there is a case for finer diversification. First, there are blue-chip dividend stocks with stable cash flows and relatively muted dividend growth.
Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer
05:10pm, Friday, 12'th Jan 2024
The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat newly diagnosed patien
The 3 Best Blue-Chip Stocks to Buy in January 2024
06:04pm, Wednesday, 10'th Jan 2024
Investing in the best blue-chip stocks offers some benefits, especially lower volatility. Typically, these stocks are stable companies with a lower beta than their peers.
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
08:01am, Wednesday, 10'th Jan 2024
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Biotech ETFs Stage Solid Comeback at the Start of 2024
12:47pm, Tuesday, 09'th Jan 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
09:01am, Tuesday, 09'th Jan 2024
Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.
Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)
12:39am, Tuesday, 09'th Jan 2024
Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)
